BrainStorm Cell Therapeutics Announces First Quarter 2022 Financial Results and Provides a Corporate Update
BrainStorm Cell Therapeutics Inc. (BCLI) announced financial results for Q1 2022, reporting a net loss of $5.4 million, down from $6.7 million in Q1 2021. Cash and equivalents decreased to $18.4 million from $22.1 million at the end of 2021. The company is enhancing its leadership team with new appointments, focusing on the advancement of its ALS treatment, NurOwn®. Promising Phase 3 data has been shared, indicating significant effects on ALS biomarkers. BrainStorm continues to engage with ALS experts and plans to present at upcoming conferences.
- Promising Phase 3 data indicating significant effects on ALS biomarkers.
- Decrease in net loss from $6.7 million in Q1 2021 to $5.4 million in Q1 2022.
- Strengthening of executive team for anticipated growth.
- Cash reserves decreased to $18.4 million from $22.1 million.
- Research and development expenses reduced to $2.6 million from $4.3 million, indicating possible funding challenges.
BrainStorm continues to gain insights and perspectives from leading ALS experts as it seeks the optimal path forward to provide broad patient access to NurOwn®
Strengthened executive team in preparation for anticipated growth and corporate development, with the appointment of Netta Blondheim-Shraga, PhD, as VP of Research & Development and Antal Pearl-Lendner, Avd, as Chief Legal Counsel
Conference call and webcast at 8:00 a.m. Eastern Time today
NEW YORK, May 16, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the financial results for the first quarter ended March 31, 2022 and provided a corporate update.
"We remain firmly committed to addressing the urgent needs of ALS patients by working expeditiously towards our goal of enabling broad access to NurOwn®," said Chaim Lebovits, Chief Executive Officer. "Our efforts here are bolstered by peer-reviewed Phase 3 data that provide evidence of NurOwn's greater treatment effects for ALS patients with less advanced disease, and by our ongoing interactions with the broader physician and patient community. These have allowed us to gain valuable perspective from the world's most prominent thought leaders as we seek NurOwn's optimal path forward. Looking ahead, we will continue to leverage expert feedback as we work with the regulatory authorities to enable NurOwn's advancement. We believe our strong clinical and biomarker data and highly talented leadership team has us poised for sustained success."
First Quarter 2022 and Recent Highlights
- Biomarker analyses from NurOwn's Phase 3 trial in ALS were presented by James Berry, MD, MPH, Winthrop Family Scholar in ALS Sciences, Director of the Massachusetts General Hospital Multidisciplinary ALS Clinic and Chief of the Division of ALS and Motor Neuron Diseases, in an abstract at the American Academy of Neurology 2022 Virtual Congress. These results demonstrated significant changes across multiple cerebrospinal fluid biomarkers following NurOwn treatment, with the strongest effects observed in biomarkers related to neuroprotection and neuroinflammation.
- Presented a prospective genetic analyses from NurOwn's Phase 3 ALS trial suggesting that NurOwn treatment may influence disease progression in patients carrying the ALS UNC13A risk allele. The presentation was featured in a late-breaking oral session at the 2022 Muscular Dystrophy and Association (Clinical & Scientific Conference) and delivered by Merit E. Cudkowicz, MD, MSc, Chief of Neurology at Massachusetts General Hospital, Julieanne Dorn Professor of Neurology at Harvard Medical School, and Director of the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital.
- Presented preclinical data demonstrating greater macrophage immunomodulation of NurOwn-derived exosomes (Exo MSC-NTF) compared to naïve mesenchymal stem cell-derived exosomes (Exo MSC) against acute lung injury at the International Society of Cell & Gene Therapy (ISCT) 2022 Meeting. The presentation was delivered by Dr. Kim Thacker, Senior Vice President, Medical Affairs and Clinical Innovation, BrainStorm Cell Therapeutics.
- Announced upcoming presentations at the ALS Drug Development Summit (May 25, 2022) and the ISEV 2022 Annual Meeting (May 26, 2022). The ALS Drug Development Summit presentation by Ralph Kern MD MHSc, President and Chief Medical Officer Brainstorm Cell Therapeutics, will focus on the use of cerebrospinal fluid biomarkers to interrogate multiple neuroinflammatory, neurodegenerative and neuroprotection pathways in NurOwn's Phase 3 ALS trial and how this information may be leveraged to confirm ALS target engagement and improve therapeutic outcomes. The ISEV presentation features the results of a preclinical study examining the advantages of Exo MSC-NTF over Exo MSC in models of acute lung injury and will be presented by Haggai Kaspi PhD, Brainstorm R&D.
- Strengthened the Company's executive team in preparation for anticipated growth and corporate development, with the appointments of Netta Blondheim-Shraga, PhD, as VP of Research & Development and Antal Pearl-Lendner, Adv, as Chief Legal Counsel.
- Granted a new Brazilian patent covering methods of manufacturing NurOwn titled - A method of generating cells which secrete Brain Derived Neurotrophic Factor (BDNF), Glial Derived Neurotrophic Factor (GDNF), Hepatocyte Growth Factor (HGF) And Vascular Endothelial Growth Factor (VEGF), wherein said cells do not Secrete Nerve Growth Factor (NGF).
- Presented a corporate and Phase 3 ALS clinical overview at the 12th Annual California ALS Research Summit on January 27, 2022 by Ralph Kern MD MHSc, President and Chief Medical Officer Brainstorm Cell Therapeutics.
Financial Results for the First Quarter Ended March 31, 2022
Cash, cash equivalents, and short-term bank deposits were approximately
Research and development expenses for the three months ended March 31, 2022, and 2021 were approximately
General and administrative expenses for the three months ended March 31, 2022, and 2021 were approximately
Net loss for the three months ended March 31, 2022, was approximately
Net loss per share for the three months ended March 31, 2022, and 2021 was
Conference Call and Webcast
May 16, 2022, at 8:00 a.m. Eastern Time
Participant Numbers: | |
Toll Free: | 888-506-0062 |
International: | 973-528-0011 |
Entry Code: | 476792 |
Webcast URL: | |
Those that wish to listen to the replay of the conference call can do so by dialing the numbers below. The replay will be available for 14 days.
Toll Free: | 877-481-4010 |
International: | 919-882-2331 |
Replay Passcode: | 45459 |
The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase 3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive multiple sclerosis (MS) and was supported by a grant from the National MS Society (NMSS).
Safe-Harbor Statement
Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may," "should," "would," "could," "will," "expect," "likely," "believe," "plan," "estimate," "predict," "potential," and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of BrainStorm's NurOwn® treatment candidate, the success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our products and services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn® treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture and commercialize the NurOwn® treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation; the impacts of the COVID-19 pandemic on our clinical trials, supply chain, and operations; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.
CONTACTS
Investor Relations:
John Mullaly
LifeSci Advisors, LLC
Phone: +1 617-429-3548
jmullaly@lifesciadvisors.com
Media:
Uri Yablonka
uri@brainstorm-cell.com
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES | ||||||
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||
U.S. dollars in thousands | ||||||
(Except share data) | ||||||
March 31, | December 31, | |||||
2022 | 2021 | |||||
U.S. $ in thousands | ||||||
ASSETS | ||||||
Current Assets: | ||||||
Cash and cash equivalents | $ | 15,151 | $ | 18,856 | ||
Short-term deposit (Note 4) | 3,246 | 3,238 | ||||
Other accounts receivable | 61 | 86 | ||||
Prepaid expenses and other current assets (Note 5) | 802 | 1,100 | ||||
Total current assets | 19,260 | 23,280 | ||||
Long-Term Assets: | ||||||
Prepaid expenses and other long-term assets | 27 | 27 | ||||
Operating lease right of use asset (Note 6) | 5,380 | 4,781 | ||||
Property and Equipment, Net | 1,124 | 1,189 | ||||
Total Long-Term Assets | 6,531 | 5,997 | ||||
Total assets | $ | 25,791 | $ | 29,277 | ||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
Current Liabilities: | ||||||
Accounts payables | $ | 4,570 | $ | 3,700 | ||
Accrued expenses | 71 | 83 | ||||
Operating lease liability (Note 6) | 1,629 | 1,461 | ||||
Other accounts payables | 1,102 | 1,073 | ||||
Total current liabilities | 7,372 | 6,317 | ||||
Long-Term Liabilities: | ||||||
Operating lease liability (Note 6) | 3,932 | 3,618 | ||||
Total long-term liabilities | 3,932 | 3,618 | ||||
Total liabilities | $ | 11,304 | $ | 9,935 | ||
Stockholders' Equity: | ||||||
Stock capital: (Note 7) | 12 | 12 | ||||
Common Stock of | ||||||
Additional paid-in-capital | 193,495 | 192,990 | ||||
Treasury stocks | (116) | (116) | ||||
Accumulated deficit | (178,904) | (173,544) | ||||
Total stockholders' equity | 14,487 | 19,342 | ||||
Total liabilities and stockholders' equity | $ | 25,791 | $ | 29,277 | ||
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES | |||||||||
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) | |||||||||
U.S. dollars in thousands | |||||||||
(Except share data) | |||||||||
Three months ended | |||||||||
March 31, | |||||||||
2022 | 2021 | ||||||||
Unaudited | |||||||||
Operating expenses: | |||||||||
Research and development, net (Note 8) | $ | 2,616 | $ | 4,341 | |||||
General and administrative | 2,859 | 2,588 | |||||||
Operating loss | (5,475) | (6,929) | |||||||
Financial income, net | 115 | 267 | |||||||
Net loss | $ | (5,360) | $ | (6,662) | |||||
Basic and diluted net loss per share from continuing operations | $ | (0.15) | $ | (0.19) | |||||
Weighted average number of shares outstanding used in computing basic | 36,436,882 | 35,791,309 | |||||||
Logo - https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-announces-first-quarter-2022-financial-results-and-provides-a-corporate-update-301547718.html
SOURCE BrainStorm Cell Therapeutics Inc
FAQ
What were BrainStorm's financial results for Q1 2022?
What is the significance of the Phase 3 data for NurOwn®?
Who has been appointed to the executive team at BrainStorm?
What is the current cash position of BrainStorm as of Q1 2022?
When is BrainStorm's next conference presentation?
